The fourth quarter of 2025 capped a period of important progress for PDS Biotech, marked by meaningful advances across our ...

NEW YORK, NY / ACCESSWIRE / December 5, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently ...

Greetings. Welcome to PDS Biotech Second Quarter 2022 Earnings Call and Webcast. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal ...

PDS Biotechnology is a mid- to late-stage clinical development company working in the area of cancer immunotherapy, with a current focus on HPV-associated cancers. Dr. Frank Bedu-Addo has served as ...

Dr. Bedu-Addo has served as a director, president and CEO of PDS Biotech since its inception in 2005. Dr. Bedu-Addo is a veteran biotech executive with experience successfully starting and growing ...

Florham Park, New Jersey--(Newsfile Corp. - March 17, 2021) - PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious ...

Greetings and welcome to PDS Biotechnology Second Quarter 2021 Financial Results. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over ...